Mixed assessment for ING product
ING's recently launched MoneyForLife product has received a solid endorsement from the ratings house Adviser Edge, but this came with a warning that both MoneyForLife and AXA's North product only provide a clear benefit in a limited range of circumstances.
Releasing Adviser Edge's assessment of the ING product, the rating agency's head of structured products, Geoff Watkins, said it represented an important improvement over existing annuity products in that it attempted to address the real problem of financing an increasing life expectancy.
"The design is easy for investors to use and understand, and it provides the secure long-term backing of a life insurance policy - which is important for investors considering retirement income for late in life," he said.
However, Watkins said that quantitative testing of the MoneyForLife investment structure revealed it might only be of investment merit in limited circumstances.
"The product should be seen as insurance. It may satisfy some clients' need for security, but at a cost - and in many instances, the monetary cost is likely to outweigh the benefit," he said.
Watkins said the key message for advisers was that the products only provided a clear benefit in a limited range of circumstances and, as such, determining investor suitability was paramount to gauging whether there was a likelihood of achieving a benefit over the long term.
Recommended for you
With wealth management M&A appetite only growing stronger, Business Health has outlined the major considerations for buyers and sellers to prevent unintended misalignment between the parties.
Industry body SIAA has said the falling number of financial advisers in Australia is a key issue impacting the attractiveness and investor participation of both public and private markets.
As advisers risk losing two-thirds of FUA during the $3.5 trillion wealth transfer, two co-founders underscore why fostering trust with the next generation is vital to retaining intergenerational wealth.
As advisers seek greater insights into FSCP determinations, what are the various options considered by the panel and can a decision be appealed?
